Printed From:

Dosing for the SYNVISC® Family


Dosing options to suit your patients’ needs1,2

  • 3 2-mL injections 1 week apart.
    SYNVISC can be administered using an 18- to 22-gauge needle1
  • 1 single 6-mL injection.
    Synvisc-One® can be administered using an 18- to 20-gauge needle2

Synvisc-One is the only FDA-approved, single-injection viscosupplement to meet its primary end point of superiority at week 26 in a randomized, head-to-head, placebo-controlled clinical study.2,4-6

References

  1. SYNVISC (hylan G-F 20) [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  2. Synvisc-One (hylan G-F 20) [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  3. Conrozier T, Jerosch J, Beks P, et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009;129(3):417-423.
  4. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113-119.
  5. Gel-One summary of safety and effectiveness data. Silver Spring, MD: US Food and Drug Administration; 2016.
  6. Monovisc summary of safety and effectiveness data. Silver Spring, MD: US Food and Drug Administration; 2014.

Injection Demonstration
Video

Learn proper needle placement and
how to inject Synvisc-One®

View Demonstration ›

Order Synvisc-One® and SYNVISC®

Learn about the different ordering options and how to get next-day delivery with your MySynviscONE™ account.

Order now ›

Resources for
Your Patients

Share these tools to help patients get the most out of their treatment.

Browse Resources ›